Defining trajectories of response in patients with psoriasis treated with biologic therapies
Article 2021 en
Authors
NG
Nophar Geifman
NA
Narges Azadbakht
JZ
J. Zeng
Abstract
1 min read
These subgroups, defined by change in disease over time, may be indicative of distinct endotypes driven by different biological mechanisms and may help inform the management of patients with psoriasis. Future work will aim to further delineate these mechanisms by extensively characterizing the subgroups with additional molecular and pharmacological data.
Nophar Geifman, Narges Azadbakht, J. Zeng, Tom Wilkinson, Nick Dand, Iain Buchan, Deborah Stocken, P. Di Meglio, Richard B. Warren, Juliet N. Barker, NJ Reynolds, Michael R. Barnes, Catherine Smith, Christopher Em Griffiths, Niels Peek
A. Rider, Henry J. Grantham, Graham R. Smith, David Watson, John Casement, Simon Cockell, Jack Gisby, Amy Foulkes, Rafael Henkin, Wasim Iqbal, Tom Ewen, Shoba Amarnath, Sandra Ng, Paolo Zuliani, Nick Dand, Deborah Stocken, Christopher Traini, E Thomas, Shanker Kalyana‐Sundaram, Deepak K. Rajpal, Kathleen M. Smith, Juliet N. Barker, Christopher Em Griffiths, Paola Di Meglio, Catherine Smith, Richard B. Warren, Michael R. Barnes, Nick J. Reynolds
Wolfram Sterry, Juliet N. Barker, Wolf‐Henning Boehncke, J.D. Bos, Sergio Chimenti, Enno Christophers, M. de la Brassinne, Christopher Em Griffiths, Andreas Katsambas, Knud Kragballe, Charles Lynde, Alan Menter, J.‐P. Ortonne, Kim Papp, Jörg C. Prinz, Berthold Rzany, J.R. Rönnevig, J.‐H. Saurat, Mona Ståhle, Fernando Stengel, P.C.M. van de Kerkhof, John J. Voorhees
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.